0000950170-23-071631.txt : 20231219 0000950170-23-071631.hdr.sgml : 20231219 20231219175559 ACCESSION NUMBER: 0000950170-23-071631 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231215 FILED AS OF DATE: 20231219 DATE AS OF CHANGE: 20231219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Crowley John F CENTRAL INDEX KEY: 0001400973 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 231498734 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: (215) 921-7600 MAIL ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 ownership.xml 4 X0508 4 2023-12-15 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001400973 Crowley John F 47 HULFISH STREET PRINCETON NJ 08542 true true false false Executive Chairman true Common Stock 2023-12-15 4 S false 6043 12.6619 D 877748 D Common Stock 2023-12-18 4 A false 34572 0.0 A 912320 D Common Stock 64895 I By Trust This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.51 to $12.83 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents a contingent right to receive common stock in the amount shown, for no consideration, due to the satisfaction of performance criteria underlying an award of performance based restricted stock units granted in 2021. Such units remain outstanding on the date hereof and will fully vest on December 31, 2023, subject to the Reporting Person's continued service with the Company. All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022. In addition to the reported transactions, Mr. Crowley also has approximately 845,000 options outstanding and exercisable at various strike prices. /s/ Christian Formica, Attorney-in-Fact 2023-12-19